Lupus Foundation of America Congratulates Aurinia Pharmaceuticals on FDA Approval of Lupkynis™ (voclosporin) to Treat Lupus Nephritis
First FDA-approved oral treatment for lupus nephritis represents a significant milestone for people living with lupus-related kidney disease, a leading cause of disability and mortality in lupus
News provided by
Share this article
Share this article
WASHINGTON, Jan. 22, 2021 /PRNewswire/ -- For the second time in less than two months, the U.S. Food and Drug Administration (FDA) has approved a new medication to treat adults with lupus nephritis (lupus-related kidney disease) in combination with a background immunosuppressive therapy regimen. Today, Aurinia Pharmaceuticals announced they received authorization from the FDA to market Lupkynis™ (voclosporin), a first-ever oral therapy for lupus nephritis that blocks a protein in the immune system called calcineurin. The company previously had reported positive data from a late-stage clinical study that demonstrated Lupkynis was superior to standard of care for treating lupus nephritis.